Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2013. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation allocations rather than operational financial performance.
Material Changes
On March 28, 2013, Non-Executive Directors were allocated notional Ordinary Shares at a price of £15.25 per share and notional American Depositary Shares (ADSs) at a price of $46.43 per ADS. These allocations covered the service period from January 1, 2013, to March 31, 2013. The Company and Directors were informed of these allocations on April 3, 2013.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Non-Executive Directors received notional share allocations for the first quarter of 2013.
- The allocation price was £15.25 per Ordinary Share and $46.43 per ADS.
- Allocations were distributed to 12 Non-Executive Directors, including Sir Christopher Gent, Professor Sir Roy Anderson, and Dr Stephanie Burns.
- This filing does not contain financial performance data or strategic outlook.